Onyvax Company

Onyvax develops cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells.

Last Funding Type: Series C
Funding Status: Late Stage Venture
Headquarters: Bradford, Somerset, United Kingdom
Founded Date: 1997-01-01
Last Funding Date: 2006-05-08
Total Funding: 29810445
Employee Number: 11-50
Investors Number: 5
Industry: Whole-Cell Antigens